Surrogate end points and their role in clinical trial

Indian Journal of Pharmacology

Volumn 41, Issue 1, 2009, Pages 54-

  Jaykaran, ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

TINOSPORA CORDIFOLIA EXTRACT;

CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; SYMPTOM;

EID: 64149122955     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.48880     Document Type: Letter

References (5)

1. Kalikar MV, Thawani VR, Varadpande UK, Sontakke SD, Singh RP, Khiyani RK. Immunomodulatory effect of Tinospora cordiofolia extract in human immunodeficiency virus positive patients. Indian J Pharmacol 2008;40: 107-10.
2. CONCORDE Coordinating Committee. CONCORE MRC/ANRS randomized double blind controlled of immediate and deferred zidovudine in symptom free HIV infection. Lancet 1994;343:871-81.
3. Epstein AE, Hallstorm AO, Rogers WJ, Liebson PR, Seals AA, Anderson JL, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide and morisizine after myocardial infarction. JAMA 1993;270:2451-5.
4. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic / pharmcodynamic surrogate markers to outcome: Focus on antibacterial agents. Clin Pharmacokinetic 1995;28:143-60.
5. Greenhalgh T. How to read a paper? BMJ 1997;315:93.